Hubert Fernandez, MD

Hubert Fernandez, MD
 

Center for Neurological Restoration
Professor of Medicine (Neurology)
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Neurological Institute, Cleveland Clinic
Cleveland, Ohio

Can you please provide us with a brief summary of what you plan to cover on today’s CME program and your assessment of unmet needs in the treatment of PD? Video

Can you please provide us with a brief summary of what you plan to cover on today’s CME program and your assessment of unmet needs in the treatment of PD?

Can you please provide us with a brief summary of what you plan to cover on today’s CME program and your assessment of unmet needs in the treatment of PD?
Hubert Fernandez, MD

Hubert Fernandez, MD

Can you provide some background on the disease burden associated with Parkinson’s Disease, and the challenges of confirming the diagnosis and heterogeneity in clinical presentation? Video

Can you provide some background on the disease burden associated with Parkinson’s Disease, and the challenges of confirming the diagnosis and heterogeneity in clinical presentation?

Can you provide some background on the disease burden associated with Parkinson’s Disease, and the challenges of confirming the diagnosis and heterogeneity in clinical presentation?
Hubert Fernandez, MD

Hubert Fernandez, MD

What are the canonical signs, symptoms and historical features of PD, and what criteria must be met to confirm the diagnosis and consider initiation of pharmacologic therapy? Video

What are the canonical signs, symptoms and historical features of PD, and what criteria must be met to confirm the diagnosis and consider initiation of pharmacologic therapy?

What are the canonical signs, symptoms and historical features of PD, and what criteria must be met to confirm the diagnosis and consider initiation of pharmacologic therapy?
Hubert Fernandez, MD

Hubert Fernandez, MD

What minimal diagnostic criteria or clinical symptom severity do you feel is required to be actionable for pharmacologic treatment in a person presenting with a sign-symptom complex suggestive of PD? Video

What minimal diagnostic criteria or clinical symptom severity do you feel is required to be actionable for pharmacologic treatment in a person presenting with a sign-symptom complex suggestive of PD?

What minimal diagnostic criteria or clinical symptom severity do you feel is required to be actionable for pharmacologic treatment in a person presenting with a sign-symptom complex suggestive of PD?
Hubert Fernandez, MD

Hubert Fernandez, MD

Once you are confident with the diagnosis of PD, and you determine that pharmacologic therapy is warranted, what kind of clinical decision tree do you rely on to determine your initial, individualized choice for treatment? Video

Once you are confident with the diagnosis of PD, and you determine that pharmacologic therapy is warranted, what kind of clinical decision tree do you rely on to determine your initial, individualized choice for treatment?

Once you are confident with the diagnosis of PD, and you determine that pharmacologic therapy is warranted, what kind of clinical decision tree do you rely on to determine your initial, individualized choice for treatment?
Hubert Fernandez, MD

Hubert Fernandez, MD

Once you commit to carbidopa/levodopa therapy, what is the typical starting dose, how long does it take for symptoms to ameliorate, and what should you expect in terms of long-term stability and/or deterioration of motor symptoms over time? Video

Once you commit to carbidopa/levodopa therapy, what is the typical starting dose, how long does it take for symptoms to ameliorate, and what should you expect in terms of long-term stability and/or deterioration of motor symptoms over time?

Once you commit to carbidopa/levodopa therapy, what is the typical starting dose, how long does it take for symptoms to ameliorate, and what should you expect in terms of long-term stability and/or deterioration (adverse fluctuations of ...
Hubert Fernandez, MD

Hubert Fernandez, MD

Given that CD/LD therapy for PD is highly individualized, what are possible advantages of longer-acting formulations of CD/LD and/or the availability of a scored, fractionable formulation of CD/LD highly amenable to titration? Video

Given that CD/LD therapy for PD is highly individualized, what are possible advantages of longer-acting formulations of CD/LD and/or the availability of a scored, fractionable formulation of CD/LD highly amenable to titration?

Given that CD/LD therapy for PD is highly individualized, what are possible advantages of longer-acting formulations of CD/LD and/or the availability of a scored, fractionable formulation of CD/LD highly amenable to titration by the patient or the physician?
Hubert Fernandez, MD

Hubert Fernandez, MD

"Off time” may vary in severity at different times during the day due to physical activity and other factors, does this support the need to have different dosing options available in the manner provided by a scored, fractionated formulation of CD/LD? Video

"Off time” may vary in severity at different times during the day due to physical activity and other factors, does this support the need to have different dosing options available in the manner provided by a scored, fractionated formulation of CD/LD?

"Off time” may vary in severity at different times during the day due to physical activity and other factors, does this support the need to have different dosing options available in the manner provided by a scored, fractionated formulation of CD/LD?
Hubert Fernandez, MD

Hubert Fernandez, MD